RecruitingCryoglobulinemic Vasculitis (CV)Drug-induced VasculitisEosinophilic Granulomatosis With Polyangiitis (EGPA)
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Eligible age
5+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.
Sponsor: Peter Merkel
You may qualify if…
- ✓ Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis
- ✓ Have a suspected or confirmed diagnosis of:
- ✓ Cryoglobulinemic vasculitis (CV)
- ✓ Drug-induced vasculitis
- ✓ Eosinophilic granulomatosis with polyangiitis (EGPA)
- ✓ IgA vasculitis
- ✓ Isolated cutaneous vasculitis
- ✓ Granulomatosis with polyangiitis (GPA)
You may not qualify if…
- ✕ You are less than five years old
- ✕ Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy
- ✕ You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dL
- ✕ You have an uncontrolled disease that could prevent you from completing the study procedures
- ✕ You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study
- ✕ You are pregnant or nursing
- ✕ You are not able to provide informed consent
Where it's recruiting
California
Los Angeles
Massachusetts
Boston
Minnesota
Rochester
Ohio
Cleveland
Oregon
Portland
Pennsylvania
Philadelphia
Utah
Salt Lake City
Virginia
Charlottesville
Source: ClinicalTrials.gov · NCT03004326 · last updated 2026-01-22